In silico evaluation of corneal patch eluting anti-VEGF agents concept

Heljak M. K., CESUR S., Ilhan E., Swieszkowski W., GÜNDÜZ O., Kijeńska-Gawrońska E.

European Journal of Pharmaceutics and Biopharmaceutics, cilt.204, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 204
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1016/j.ejpb.2024.114494
  • Dergi Adı: European Journal of Pharmaceutics and Biopharmaceutics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: Anti-VEGF, Controlled release, Corneal patch, In silico, Microbial keratitis
  • Marmara Üniversitesi Adresli: Evet

Özet

This study introduces a novel approach utilizing a temporary drug-eluting hydrogel corneal patch to prevent neovascularization, alongside a numerical predictive tool for assessing the release and transport kinetics of bevacizumab (BVZ) after the keratoplasty. A key focus was investigating the impact of tear film clearance on the release kinetics and drug transport from the designed corneal patch. The proposed tear drug clearance model incorporates the physiological mechanism of lacrimal flow (tear turnover), distinguishing itself from previous models. Validation against experimental data confirms the model's robustness, despite limitations such as a 2D axisymmetrical framework and omission of blink frequency and saccadic eye movements potential effects. Analysis highlights the significant influence of lacrimal flow on ocular drug transport, with the corneal patch extending BVZ residence time compared to topical administration. This research sets the stage for exploring multi-layer drug-eluting corneal patches as a promising therapeutic strategy in ocular health.